Clinical trial

Avandamet Bioequivalence Study Brazil - Fed Administration

NCT01332071

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2009-11-24

PhasePHASE1

Study timeline

Study start (actual)2009-11-24Date precision: day

Registry last updated2017-07-12

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Diabetes Mellitus, Type 2verified · MONDO: type 2 diabetes mellitus

Interventions

Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mgDRUG

Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mgDRUG

Sponsors & collaborators

GlaxoSmithKlinelead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01332071 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.